Upperton Rebrands to Showcase Expanded CDMO Capabilities

Editor’s Take: Rising pharmaceutical tariffs and geopolitical uncertainty have increased the cost and complexity of global drug production, prompting companies to reassess supply-chain efficiency and security. As a result, CDMOs with integrated, end-to-end capabilities at a single U.S. facility are becoming preferred partners.

Upperton has unveiled a new brand identity, marking a milestone in the company’s evolution into a specialist, end-to-end contract development and manufacturing organization (CDMO) focused on solving the challenges of molecule development across oral, nasal, pulmonary and parenteral dosage forms.

The new brand reflects the transformation of Upperton over recent years, driven by significant investment in infrastructure, scientific expertise and manufacturing capability.

The new positioning also reflects how Upperton works today: combining formulation development, analytical science, clinical manufacturing and commercial-scale production within a single-site designed to support small molecule and biologics drug products throughout the drug development lifecycle.

Nikki Whitfield, CEO of Upperton, explains, “We’re seeing biotech and pharma companies developing some of the most exciting and innovative products the industry has ever seen, including novel small molecules, biologics and advanced formulations. They need a partner that can navigate complexity across development and manufacturing while providing continuity throughout the journey. That’s exactly what Upperton has been built to deliver.”

The company’s capabilities span oral solid dose, nasal, pulmonary and sterile drug products, giving customers access to specialized expertise across a range of delivery routes within a single development and manufacturing partner.

By combining advanced formulation science with flexible development and manufacturing capabilities, Upperton supports customers whose programs require a higher level of scientific engagement, innovation and problem-solving than traditional outsourcing models can provide.

As it enters its next phase of growth, Upperton says it remains focused on helping pharmaceutical and biotechnology companies overcome development complexity, accelerate timelines and successfully advance innovative molecules.